ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation

Transplantation

Volumn 89, Issue 1, 2010, Pages 75-82

  Taegtmeyer, Anne B ^a,b   Breen, Jane B ^a   Smith, John ^a   Burke, Margaret ^a   Leaver, Neil ^a   Pantelidis, Panagiotis ^c   Lyster, Haifa ^a   Yacoub, Magdi H ^b   Barton, Paul J R ^b   Banner, Nicholas R ^a,c  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

ABCB1; Acute rejection; Cardiac transplantation.; Cyclosporin

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; EVENING DOSAGE; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; CYCLOSPORINE; FEMALE; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 74549218800     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c342fd     Document Type: Article

References (35)

1. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189.
2. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473.
3. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525.
4. Anglicheau D, Legendre C, Thervet E. Pharmacogenetics in solid organ transplantation: Present knowledge and future perspectives. Transplantation 2004; 78: 311.
5. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89.
6. Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exon 21 and 26 predict steroid weaning in paediatric heart transplant patients. Hum Immunol 2002; 63: 765.
7. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 2006; 82: 1677.
8. Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451.
9. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosup-pressants:Aperspectiveonethnic differences. IntJClin Pharmacol Ther 2004; 42: 701.
10. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225.
11. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921.
12. Schumann G, Petersen D, Hoyer PF, et al. Monitoring cyclosporine A (ciclosporin, INN) concentrations in whole blood: Evaluation of the EMIT assay in comparison with HPLC and RIA. Eur J Clin Chem Clin Biochem 1993; 31: 381.
13. Billingham ME, Cary NR, Hammond ME, et al. Aworking formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
14. Levey AS, Coresh J, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glo-merular filtration rate. Ann Intern Med 2006; 145: 247.
15. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169.
16. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. BMJ 1995; 310: 170.
17. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451.
18. Fellay J, Marzolini C, Meaden E, et al; Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmaco-genetics study. Lancet 2002; 359: 30.
19. Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acidinduodenal enterocytesofhealthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297.
20. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422.
21. Mai I, Störmer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003; 43: 1101.
22. Foote CJ, Greer W, Kiberd BA, et al. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc 2006; 38: 2847.
23. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048.
24. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
25. Hesselink DA, van Schaik RH, van der Heider, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacoki-netics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
26. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp Clin Transplant 2006; 4: 416.
27. Wang W, Zhang XD, Guan DL, et al. Relationship between MDR1 polymorphism and blood concentration of cyclosporine A. Chin Med J (Engl) 2005; 118: 2097.
28. Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380.
29. Jiang ZP, Wang YR, Xu P, et al. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 2008; 103: 433.
30. Hamour IM, Burke MM, Bell AD, et al. Limited utility of endomyocar-dial biopsy in the first year after heart transplantation. Transplantation 2008; 85: 969.
31. Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1206.
32. Zheng HX, Zeevi A, McCurry K, et al. The impact ofpharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005; 14: 37.
33. Hamour IM, Omar F, Lyster HS, et al. Chronic kidney disease after heart transplantation. Nephrol Dial Transplant 2009; 24: 1655.
34. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802.
35. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.